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Background. Conflicting effects of neuromuscular blocking drugs and anticholinesterases on
depth of anaesthesia have been reported. Therefore we evaluated the effect of atracurium and
neostigmine on bispectral index (BIS) and middle-latency auditory evoked potentials (AAI).
Methods. We studied 40 patients (ASA I–II) aged 18–69 yr. General anaesthesia consisted of
propofol and remifentanil by target-controlled infusion and neuromuscular function was mon-
itored by electromyography.When BIS reached stable values, patients were randomly assigned to
one of two groups. Group 1 received atracurium 0.4 mg kg1 and, 5 min later, the same volume of
NaCl 0.9%; group 2 received saline first and then atracurium. When the first twitch of a train of
four reached 10% of control intensity, patients were again randomized: one group (N) received
neostigmine 0.04 mg kg1 and glycopyrrolate 0.01 mg kg1, and the control group (G) received
only glycopyrrolate.
Results. Injection of atracurium or NaCl 0.9% had no effect on BIS or AAI. After neostigmine–
glycopyrrolate, BIS and AAI increased significantly (mean maximal change of BIS 7.1 [SD 7.5],
P<0.001; mean maximal change of AAI 9.7 [10.5], P<0.001). When glycopyrrolate was injected
alone BIS and AAI also increased (mean maximal change of BIS 2.2 [3.4], P=0.008; mean maximal
change of AAI 3.5 [5.7], P=0.012), but this increase was significantly less than in group N (P=0.012
for BIS; P=0.027 for AAI).
Conclusion. These data suggest that neostigmine alters the state of propofol–remifentanil
anaesthesia and may enhance recovery.
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Clinically, it has been suspected that reversing neuromus-
cular block by injection of an anticholinesterase agent may
induce arousal and even awareness.1 2 On the other hand,
injection of a neuromuscular blocking drug appears to
deepen the level of anaesthesia.3 Meuret and colleagues2
have reported reversal of propofol-induced unconsciousness
by physostigmine, an anticholinesterase that crosses the
blood–brain barrier. This is probably a result of altered cent-
ral cholinergic transmission. Indeed, it is postulated that
inhibition of central cholinergic transmission may play an
important role in the mechanism by which general anaes-
thetic drugs produce unconsciousness.2 4 5 Physostigmine
has also been shown to increase the amount of propofol
required to induce loss of consciousness.1
Neostigmine, which is the anticholinesterase agent com-
monly used in clinical practice, does not cross the blood–
brain barrier.6 Therefore the central mechanism by which
physostigmine may induce arousal is not applicable to
neostigmine. The afferentation theory states that signals
from muscle stretch receptors (proprioception) stimulate
arousal centres in the brain.7 This theory has, in part,
been confirmed by some studies: neuromuscular block
has been reported to reduce the minimum alveolar concen-
tration (MAC) by 25%,3 and active muscle movement in
lightly anaesthetized dogs had an activating effect on the
electroencephalogram, whereas paralysis with pancuronium
abolished movement-induced stimulation.7 However, other
studies have failed to confirm these findings,8 9 and no study
so far has investigated the effect of neostigmine on the depth
of anaesthesia as assessed by bispectral index (BIS).
Therefore the aim of this study was to evaluate the
variation in the depth of anaesthesia during propofol–
remifentanil anaesthesia, as assessed by BIS and middle-
latency auditory evoked potentials (A-Line autoregressive
index [AAI]) induced by either muscle relaxation or antag-
onization of neuromuscular blockade.
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Methods
After institutional ethics committee approval and written
informed consent, 40 patients aged 18–69 yr, ASA status
I or II, scheduled for elective surgery requiring general
anaesthesia and intubation were included in this prospective
randomized double-blinded study. Patients were excluded if
they had cardiopulmonary, renal, hepatic or neurological
disorders, if they had a history of chronic alcohol consump-
tion and/or drug abuse, and if they were taking any med-
ication affecting neurological or neuromuscular function.
Experimental protocol
No premedication was given. Target effect site concentra-
tion was used for induction and maintenance of general
anaesthesia. The pharmacokinetic sets used to calculate
target effect site concentrations of propofol and remifentanil
were those published by Minto and colleagues10 and
Schnider and colleagues,11 respectively. Remifentanil was
kept at 3 ng ml1 and propofol was raised in incremental
steps until unconsciousness, defined by loss of verbal con-
tact. For intubation, target effect site concentration was
increased to 6 ng ml1 for remifentanil and to 6 mg ml1
for propofol. Tracheal intubation was performed without the
use of neuromuscular blocking drugs.12 13 The lungs were
mechanically ventilated with 50% oxygen in air to maintain
end-tidal Pco2 between 4.4 and 5.1 kPa. Hypotension was
treated first with 500 ml Ringers solution and then with
ephedrine 5 mg i.v.
Non-invasive blood pressure, heart rate, peripheral arter-
ial oxygen saturation and end-tidal Pco2 were recorded at
1-min intervals. Core temperature was measured using an
oesophageal thermometer (AS3 monitor, DATEX,
Helsinki, Finland). Neuromuscular function was monitored
by electromyography (EMG) with repeated train-of-four
(TOF) sequences applied via surface electrodes to the
ulnar nerve at the wrist. TOF was repeated every 20 s. The
resulting integrated EMG of the adductor pollicis muscle
was measured (ElectroSensor type M-NMT.02, DATEX,
Helsinki, Finland) to monitor muscle relaxation and
recovery. The hand was fixed to guarantee immobility
and stable responses. The first TOF sequence served as
the control reference with which all subsequent first twitches
were compared (T1%). EMG and mechanomyography are
comparably reliable in patients without neuromuscular
diseases,14 but EMG is easier to use. We were interested
in a specific predetermined endpoint (first twitch in TOF as
10% of preblock value).
The level of consciousness was assessed by BIS and AAI.
The forehead was cleaned with ether and then abraded with
gauze. BIS electrodes (ZipprepTM electrodes, Aspect Medi-
cal Systems) and AAI electrodes (A-Line auditory evoked
potential electrodes; Danmeter A/S, Odense, Denmark)
were positioned according to the manufacturer’s recom-
mendation on forehead, temple and mastoid. Depth of anaes-
thesia, as assessed by BIS (A-2000TM BISTM XP Monitor,
software version 3.4, Aspect Medical Systems Inc., Newton,
MA, USA) and AAI (A-Line Monitor, Danmeter A/S,
Odense, Denmark), and frontotemporal EMG power
(expressed in decibels with respect to 0.0001 mV2)
at 70–110 Hz (Aspect Medical Systems A-2000TM BISTM
Monitor) were recorded continuously. The middle-
latency auditory evoked potentials (MLAEP) were elicited
with a bilateral click stimulus of intensity 70 dB and
duration 2 ms.
After intubation, remifentanil target effect site concentra-
tion was decreased to 3 ng ml1 and the propofol target was
adjusted in steps of 0.1–0.5 mg ml1 to achieve a steady-
state level of anaesthesia for at least 5 min at a BIS of 55 (2).
The A-2000TM BISTM XP Monitor always recorded EMG
simultaneously with BIS.
In the first part of the study, patients were randomly
assigned to one of two groups (n=20 each). A nurse not
involved in the study prepared the study drugs based on
the randomization list. The drugs were blinded for the
investigators. Group 1 received atracurium 0.4 mg kg1
and 5 min later the same volume of NaCl 0.9%. Group 2
received these drugs in reverse order (saline, then atra-
curium). After this part of the study, anaesthesia was
again maintained at stable BIS values until the first twitch
of a TOF reached 10% of control value.15
In the second part of the study, patients were again ran-
domly assigned to one of two groups. One group (N)
received neostigmine 0.04 mg kg1 and glycopyrrolate
0.01 mg kg1; the control group (G) received only gly-
copyrrolate 0.01 mg kg1. The first and second randomiza-
tions were completely independent. Glycopyrrolate was
administered together with neostigmine to block the peri-
pheral muscarinic side-effects of neostigmine. Patients were
kept normothermic by increasing room temperature. No sur-
gery was performed during the study. After completion of
the study, anaesthesia was continued with propofol and fen-
tanyl and surgery was performed as planned. All patients
were interviewed after the operation in the recovery room
and on the ward.
The propofol target effect site concentration was noted at
the moment of injection of atracurium or saline in the first
part of the study and neostigmine and/or glycopyrrolate in
the second part.
Data analysis
For each patient, baseline values for BIS, AAI and EMG
were averaged over 1 min before injection of the assigned
study drug. Subsequently, after the injection of the neuro-
muscular blocking drug, the anticholinesterase or the con-
trol, values were averaged every minute for 5 min in the first
part of the study and for 10 min in the second part. Criteria
for termination of the recordings following neostigmine–
glycopyrrolate or glycopyrrolate were a T1% of 60% of
control value or if the patient showed clinical signs of
arousal such as coughing or opening the eyes.
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The maximal change of BIS and AAI for each group was
compared with the baseline values and between groups.
EMG at the time of maximal change of BIS was compared
with baseline values.
Statistical analysis
Statistical analysis was performed with using JMP software
(JMP version 5.0.1a, SAS Institute Inc., Cary, NC, USA).
The estimated sample size in each group was based on the
study by Meuret and colleagues.2 Accepting a type I error of
5% and a type II error of 20%, we calculated that the number
of patients necessary was n=15.6. Therefore we studied two
groups of n=20 each.
The physical characteristics between groups were com-
pared using Student’s t-test. Baseline BIS and AAI values
and the mean maximal change of BIS and AAI were com-
pared with a two-way ANOVA for repeated measurements on
one way (time), followed by paired and unpaired Student’s
t-tests with Bonferroni’s correction.
Results are expressed as mean (SD). The criterion for
statistical significance was P<0.05.
Results
The groups were similar regarding patient characteristics
(Table 1). Only two patients needed ephedrine 5 mg to
treat hypotension, which was administered in the phase
between the two parts of the study. There was no difference
between the groups at baseline for BIS or AAI (Table 2).
There was also no difference in the baseline values between
the two parts of the study. After injection of atracurium or
NaCl, no decrease was seen for BIS (mean maximal change
after injection of atracurium, 0.6 [4.7], NS; after NaCl
0.9%, 2.0 [4.1], NS; or AAI (mean maximal change after
injection of atracurium, 1.4 [12.5], NS; after NaCl 0.9%,
5.8 [12.1], NS).
In the second part of the study, the mean maximal
increase of BIS and AAI after injection of neostigmine–
glycopyrrolate was significant compared with baseline
(BIS, 7.1 [7.5], P<0.001; AAI, 9.7 [10.5], P<0.001).
When glycopyrrolate was injected alone we also noted an
increase of BIS and AAI (BIS, 2.2 [3.4], P=0.008; AAI, 3.5
[5.7], P=0.012), but this increase was significantly less than
that with neostigmine–glycopyrrolate (BIS P=0.012, AAI
P=0.027) (Fig. 1). Three patients showed unexpected
movements and coughing after injection of neostigmine.
One patient remembered this episode.
At baseline and during the first part of the study there was
no difference between the two groups with regard to hae-
modynamic values. After injection of glycopyrrolate alone,
mean arterial pressure and heart rate increased significantly
and were significantly higher than in the neostigmine–
glycopyrrolate group (Table 3).
The values of the EMG recorded by the BIS electrode at
the moment of the maximal change of BIS are shown in
Table 4. There was a significant decrease in EMG after the
injection of atracurium in groups 1 and 2. In the second part
of the study there was a significant increase in EMG after the
injection of neostigmine–glycopyrrolate.
The target effect site of propofol used to maintain BIS at
55 did not vary significantly throughout the study (baseline
part 1, 2.1 [0.5] mg ml1 vs baseline part 2, 2.0 [0.5] mg
ml1, NS) or between groups in the first and second parts
of the study (part 1: group 1, 2.1 [0.6] mg ml1 vs group 2,
2.0 [0.5] mg ml1, NS; part 2: group N, 2.1 [0.5] mg ml1
vs group G, 2.0 [0.5] mg ml1, NS).
Table 1 Patient characteristics. Values are mean (range), mean (SD) or absolute
count. Group 1, atracurium then NaCl 0.9%; group 2, NaCl 0.9% then atra-
curium; group N, neostigmine–glycopyrrolate; group G, glycopyrrolate. NS, not
significant
Group 1 Group 2 P-value Group N Group G P-value
Age (yr) 40 (19–63) 39 (18–69) NS 40 (19–69) 39 (18–61) NS
Gender
(F/M)
7/13 6/14 NS 6/14 7/13 NS
BMI
(kg m2)
23 (3) 23 (3) NS 23 (3) 24 (3) NS
ASA I/II 15/5 12/8 NS 14/6 13/7 NS
Smoker
(yes/no)
7/13 7/13 NS 6/14 8/12 NS
Table 2 Baseline (1 min before injection of the study drug) values for BIS and
AAI. Group 1, atracurium then NaCl 0.9%; group 2, NaCl 0.9% then atracurium;
group N, neostigmine–glycopyrrolate; group G, glycopyrrolate. Baseline values
were averaged over 1 min before injection of the assigned study drug. Normal
sleep ranges for BIS, 40–60; normal sleep ranges for AAI, 20–40. NS, not
significant
Group 1 Group 2 P-value Group N Group G P-value
AAI 27 (13) 23 (6) NS 23 (7) 23 (8) NS
BIS 56 (6) 56 (6) NS 54 (6) 56 (6) NS
0
5
10
15
20
25 Group neostigmine/glycopyrrolate
Group glycopyrrolate
**
*
*
**
BIS AAI
M
ax
im
u
m
 c
ha
ng
e 
vs
 
ba
se
lin
e 
fo
r 
BI
S 
or
 A
AI
†
†
Fig 1 Mean maximal change and standard deviation of BIS and AAI after
the injection of either neostigmine–glycopyrrolate or glycopyrrolate alone
(control). BIS and AAI increase significantly in both groups, but this
increase is significantly less in the glycopyrrolate group than when
neostigmine and glycopyrrolate are injected. *P<0.05, **P<0.01 for
maximum change vs baseline; {P<0.05 between groups.
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Discussion
This study shows that the anticholinesterase neostigmine
alters the depth of propofol anaesthesia and enhances recov-
ery, as assessed by BIS and AAI measurements. Moreover,
three patients showed unexpected movements and coughing
after injection of neostigmine, suggesting that it had an
arousal effect. One patient even remembered this episode.
In contrast, muscle relaxation had no effect on the depth of
anaesthesia.
This finding may have some clinical relevance. Indeed,
despite an adequate level of anaesthesia (BIS 40–60), unex-
pected patient movement during recovery of anaesthesia at
the end of operation may interfere with surgery or dressing.
Moreover, alteration of the level of anaesthesia may lead to
awareness and recall. The anaesthetic effect of neuromus-
cular blocking drugs has been discussed for many years and
clinical data are still conflicting. In 1997, Forbes and col-
leagues3 found that pancuronium reduces halothane require-
ments in humans. One possible explanation could be the
afferent muscle spindle theory, which was developed in
the 1960s and expanded by Lanier and colleagues7 to explain
their finding that paralysis by pancuronium diminishes EEG
activity in dogs. Neuromuscular blocking drugs may alter
cerebrocortical activity by changing proprioceptive afferent
activity from muscles. The afferent muscle spindle theory
predicts that agents or manoeuvres that actively or passively
cause muscle stretch or contraction will stimulate the arousal
centres in the brain. Consistent with this theory, Schwartz
and colleagues16 found that pancuronium increases the
duration of electroencephalogram burst suppression in
dogs anaesthetized with isoflurane. This increase was
reversed by neostigmine. Our study also supports this the-
ory; increases in muscle afferent activity by antagonizing the
neuromuscular block result in a sustained cerebral arousal
response during propofol–remifentanil anaesthesia.
In keeping with the afferentation theory, if a muscle relax-
ant is injected, deafferentation will occur which should
deepen the level of anaesthesia. In a study of paralysed
dogs, the cerebral response to noxious stimulation during
light halothane anaesthesia was attenuated compared with
non-paralysed dogs.7 It has recently been shown in intensive
care patients receiving light sedation (BIS 65–80) that
muscle relaxation deepens the level of anaesthesia as
assessed by BIS monitoring.17
However, Lanier and colleagues could not demonstrate
any effect of muscle relaxation or antagonism on anaesthetic
depth. The combination of neostigmine and glycopyrrolate
produced no changes in EEG, cerebral blood flow, cerebral
metabolic rate for oxygen or intracranial pressure in dogs
anaesthetized with halothane. These authors concluded that
neostigmine–glycopyrrolate had no specific cerebral effect
on paralysed dogs.
It is possible that afferentation has only a weak central
effect. Therefore, at deep levels of anaesthesia, this effect
is too small to measurably affect the level of anaesthesia.
On the other hand, during light anaesthesia, this effect may
be enough to induce arousal. Greif and colleagues9
examined the effect of muscle relaxation on BIS at different
levels of neuromuscular blockade. They found no alteration
in hypnotic level after the administration of mivacurium.
The baseline BIS level before the injection of the neuro-
muscular blocking drug was 40 (5), corresponding to a deep
hypnotic state.
The absence of an effect of atracurium on BIS and AAI in
our study is not due to a different depth of anaesthesia, as
baseline values for BIS and AAI before each part of the
Table 3 Heart rate (HR) and mean arterial pressure (MAP). HR baseline, HR before injection; HR max, HR at time of maximal change of BIS; MAP baseline, MAP
before injection; MAP max, MAP at time of maximal change of BIS; NS, not significant
HR baseline
(beats min1)
HR max
(beats min1)
MAP baseline
(mm Hg)
MAP max
(mm Hg)
Group 1: first atracurium 60 (12) 60 (12) 70 (11) 70 (12)
Group 2: first NaCl 63 (9) 63 (8) 73 (5) 74 (9)
P-value NS NS NS NS
Group 1: NaCl (5 min later) 59 (10) 59 (10) 70 (11) 70 (10)
Group 2: atracurium (5 min later) 63 (7) 63 (8) 74 (9) 72 (7)
P-value NS NS NS NS
Group N: neostigmine–glycopyrrolate 59 (9) 60 (10) 71 (10) 75 (13)
Group G: glycopyrrolate 60 (10) 77 (9) 74 (7) 85 (8)
P-value NS <0.0001 NS 0.01
Table 4 EMG (dB) before and after injection. EMG baseline, EMG values
before injection; EMG max, EMG at time of maximal change of BIS; NS, not
significant
EMG baseline
(dB)
EMG max
(dB)
P-value
Part 1
Group 1: first
atracurium
29.7 (2.4) 28.2 (1.6) 0.006
Group 2: first NaCl 31.0 (3.1) 32.0 (4.5) NS
Group 1: NaCl
(5 min later)
28.3 (1.6) 28.1 (1.6) NS
Group 2: atracurium
(5 min later)
30.5 (2.5) 28.6 (1.5) 0.039
Part 2
Group N: neostigmine–
glycopyrrolate
27.7 (1.3) 31.2 (5.3) 0.006
Group G: glycopyrrolate 29.1 (3.2) 29.7 (3.8) NS
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study were not different (Table 2). This may be related to the
fact that various muscle groups have various time courses of
muscle relaxation and therefore the disappearance of the
proprioception signal will occur slowly.19 20 On the other
hand, neostigmine may induce recovery of nearly all muscle
activity simultaneously and this may stimulate a rapid
increase in the proprioception signal.
We also measured a slight arousal effect when glyco-
pyrrolate alone was given. This increase in BIS and AAI
measurements could be explained by spontaneous recovery
of muscle function after atracurium by a similar mechanism
to the combined neostigmine–glycopyrrolate injection.
However, the increase after neostigmine–glycopyrrolate
was significantly more than with glycopyrrolate alone.
A major limitation of this study is the possible interfer-
ence of EMG activity which has been reported to increase
BIS.17 21 22 Although the potential measured by BIS is pre-
dominantly EEG, potentials from other sources like muscu-
lar activity or electrode motion may compromise the
measured signal. Appropriate filtering attenuates these arti-
facts. As the spectral power of the scalp EEG signal has a
small amplitude at relatively high frequencies, interpretation
of the EEG signal could be confounded with significant
frontal electromyographic EMG spectral power. Since
EEG and EMG artifacts overlap in the 30–50 Hz ranges,
simple filtering will not completely remove the EMG artifact
from single-channel EEG recordings. Substantial EEG
power in the 30–50 Hz range is typically associated with
awake or lightly sedated patients. EMG was continuously
recorded throughout the procedure by the BIS electrodes. In
the second part of the study the EMG values increased
significantly after injection of neostigmine–glycopyrrolate,
which was not the case when glycopyrrolate was injected
alone. Nevertheless, this increase is unlikely to be respons-
ible for the arousal effect demonstrated by BIS and AAI.
Indeed, the variation in absolute EMG values is very small
(27.7 [1.3] to 31.2 [5.3] dB after injection of neostigmine–
glycopyrrolate, compared with 29.1 [3.2] to 29.7 [3.8] after
glycopyrrolate alone), and there is no difference between the
two groups. Moreover, in the first part of the study, injection
of atracurium was associated with a significant decrease in
the EMG, but without any effect on the BIS or AAI values.
Therefore the arousal effect of neostigmine is unlikely to be
primarily caused by an EMG artifact.
A second limitation of this study is the use of atracurium.
The benzylisoquinoline derivative atracurium is a widely
used non-depolarizing neuromuscular blocking agent
which was chosen because of its relatively short half-life
and its rapid elimination period.23 It is unlikely that lauda-
nosine or atracurium cause a clinical significant effect with
the doses administrated in our study. Fahey and colleagues24
could not demonstrate measurable concentrations (>2 ng
ml1) of atracurium in cerebrospinal fluid after i.v. admin-
istration of atracurium 0.5 mg kg1.24
In conclusion, our data suggest that neostigmine alters the
state of propofol–remifentanil anaesthesia and enhances
recovery. The arousal effect recorded by BIS and AAI prob-
ably corresponds to a sudden increase in afferent signals
from muscle stretch receptors.
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